Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IRON
DISC MEDICINE, INC.
NASDAQ
$80.03
▼ DOWN 3.05% (-2.52)

KEY STATISTICS

Market Cap$3.07 B
52w High$99.50
52w Low$40.00
Dividend Yield—
Frequency—
P/E-12.09
Volume665.57K
Shares Out.38.39M

COMPANY

LEADERSHIP

John D. Quisel
CHIEF EXECUTIVE
John D. Quisel

ABOUT

SECTOR
Healthcare
WENT PUBLIC
August 12, 2020
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
165

PRICE TARGET

Target High$90.00
Target Low$90.00
Target Median$90.00
Target Consensus$90.00

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$1.88M
NOV
5
THU

SPLIT RECORD

DATETYPERATIO
2022-12-30Reverse1:10

PRICE

$80.03 ▼ DOWN 3.05% (−$2.52)
OVERLAYS
$80.25$81.00$81.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM80.03

About Disc Medicine, Inc.

https://www.discmedicine.com ↗

Disc Medicine, Inc. is a clinical-stage biotech in Watertown, MA, developing novel therapies targeting heme biosynthesis and iron homeostasis to treat serious hematologic diseases.

INDUSTRY

Biotechnology

A PRODUCT DISC MEDICINE, INC. IS KNOWN FOR

Bitopertin
Bitopertin

An investigational oral GlyT1 inhibitor in late-stage development for erythropoietic protoporphyria and hematologic diseases, serving as the company's lead and most promising near-term commercial product.

COMPETITORS

COMPETITOR
AGIO COMPARE
BBIO COMPARE
INCY COMPARE
KROS COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
127
LISTED HERE
24
RANKED BY POSITION SIZE
XBI
0.71% · 1.0M
VTS.AX
0.00% · 976.8K
IWM
0.07% · 730.0K
SCHA
0.05% · 152.3K
DFAS
0.06% · 119.6K
TMSL
0.20% · 72.1K
SBIO
1.56% · 47.1K
LABU
0.48% · 37.0K
PTH
0.87% · 29.7K
XRS2.DE
0.07% · 25.9K
FFSM
0.11% · 18.3K
RSSL
0.07% · 13.5K
BBSC
0.11% · 10.1K
BBC
0.73% · 4.6K
BIB
0.11% · 1.4K
STXK
0.10% · 1.1K
BKSE
0.09% · 956
VETS
0.18% · 823
ESSC
0.11% · 511
TILT
0.00% · 334
KBFR
0.12% · 168
USFMDN.MX
0.01% · 124
RESM
0.07% · 54
GTPE
0.00% · 19

INSTITUTIONAL OWNERSHIP

SHARES OWNED
67.80%
HOLDERS
275
TOP 12 OF 275 · RANKED BY POSITION SIZE
Fmr LLC
5.6M sh · $357.23M
Blackrock, Inc.
2.5M sh · $180.5M
Ra Capital Management, L.P.
2.5M sh · $179.21M
Atlas Venture Life Science Advisors, LLC
2.1M sh · $141.58M
Jpmorgan Chase & Co
1.9M sh · $139.87M
Price T Rowe Associates Inc /Md/
1.9M sh · $137.17M
Vanguard Group Inc
1.8M sh · $140.37M
Wellington Management Group Llp
1.7M sh · $127.36M
State Street Corp
1.7M sh · $108.59M
Vestal Point Capital, LP
1.6M sh · $113.37M
Frazier Life Sciences Management, L.P.
1.4M sh · $95.06M
Blackrock Inc.
1.4M sh · $64.79M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF OPERATING OFFICER
Yu Jonathan Yen-Wen
Purchase · 8.8K shares
2026-08-25
★
OFFICER: CHIEF OPERATING OFFICER
Yu Jonathan Yen-Wen
Purchase · 300 shares
2026-08-24
★
OFFICER: CHIEF OPERATING OFFICER
Yu Jonathan Yen-Wen
Sale · 300 shares
2026-08-24
★
OFFICER: CHIEF OPERATING OFFICER
Yu Jonathan Yen-Wen
Sale · 8.8K shares
2026-08-25

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 3
OVERWEIGHT 3
OUTPERFORM 2
STRONG BUY 1
9 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Morgan Stanley OVERWEIGHT Wedbush OUTPERFORM Wells Fargo OVERWEIGHT Truist Securities BUY BMO Capital OUTPERFORM Cantor Fitzgerald OVERWEIGHT Stifel BUY

SECTORS PEERS

PEERPRICE
APGE$134.97COMPARE
SRRK$57.80COMPARE
CGON$74.34COMPARE
XENE$59.99COMPARE
CELC$88.44COMPARE
ADPT$25.19COMPARE
LEGN$19.88COMPARE
TARS$71.76COMPARE